Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Inactivation of Enveloped Viruses and Tumor Cells for Infectious Disease and Cancer Vaccines

Posted Jun 15 2010 5:00pm

Description of Invention:
The current technology describes the inactivation of viruses, parasites, and tumor cells by the hydrophobic photoactivatable compound 1,5-iodoanpthylazide (INA). This non-toxic compound will diffuse into the lipid bilayer of biological membranes and upon irradiation with light will bind to proteins and lipids in this domain, thereby inactivating fusion of enveloped viruses with their corresponding target cells. Furthermore, the selective binding of INA to protein domains in the lipid bilayer preserves the structural integrity and therefore immunogenicity of proteins on the exterior of the inactivated virus. This technology is universally applicable to other microorganisms that are surrounded by biological membranes like parasites and tumor cells. The broad utility of the subject technology has been demonstrated using influenza virus, HIV, SIV, Ebola and equine encephalitis virus (VEE) as representative examples. The inactivation approach for vaccine development presented in this technology provides for a safe, non-infectious formulation for vaccination against the corresponding agent. Vaccination studies demonstrated that mice immunized with INA inactivated influenza, Ebola and VEE mounted a protective immune response against lethal doses of the corresponding virus. A second technology for inactivating HIV and other retroviruses by inactivation of zinc fingers is described in E-174-1993/1,/2.

Applications:
  • Vaccines against enveloped viruses, including influenza and HIV
  • Cancer vaccines


Development Status:
Animal data (mouse) available for influenza.

Inventors:
Yossef Raviv (SAIC)


Patent Status:
HHS, Reference No. E-303-2003/0
PCT, Application No. PCT/US2005/009559 filed 22 Mar 2005
HHS, Reference No. E-135-2006/1
US, Application No. 11/525,250 filed 21 Sep 2006
US, Application No. 12/225,551 filed 24 Sep 2008


Related Technologies:
US, Patent No. 6,001,555, Issued 14 Dec 1999, Reference No. E-174-1993/1
PCT, Application No. PCT/US95/11915 filed 19 Sep 1995, Reference No. E-174-1993/2
EP, Patent No. 0782632, Issued 16 Apr 2003, Reference No. E-174-1993/2
EIR, Reference No. E-174-1993/1
EIR, Reference No. E-174-1993/2
IT, Patent No. 0782632, Issued 16 Apr 2003, Reference No. E-174-1993/2
BE, Patent No. 0782632, Issued 16 Apr 2003, Reference No. E-174-1993/2
CH, Patent No. 0782632, Issued 16 Apr 2003, Reference No. E-174-1993/2
DE, Patent No. 0782632, Issued 16 Apr 2003, Reference No. E-174-1993/2
GB, Patent No. 0782632, Issued 16 Apr 2003, Reference No. E-174-1993/2
US, Patent No. 6,989,263, Issued 24 Jan 2006, Reference No. E-174-1993/1


Relevant Publication:
  1. Y Raviv et al. Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope. J Virol. 2005 Oct;79(19):12394-12400. [ PubMed abs ]


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Cancer Institute’s Membrane Structure and Function Section is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize non-infectious formulation for vaccination. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.


Portfolios:
Cancer
Cancer - Therapeutics
Infectious Diseases
Infectious Diseases - Vaccines
In-vivo Data



For Additional Information Please Contact:
Kevin Chang Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: changke@mail.nih.gov
Phone: 301-435-5018
Fax: 301-402-0220


Ref No: 932

Updated: 06/2010

Post a comment
Write a comment:

Related Searches